Cullinan Outlines Q4 2026 Immunology and Oncology Data Milestones
Cullinan Therapeutics announced four major updates for Q4 2026 across its T cell engager pipeline, including multi-dose SLE data for CLN-978 in December and Phase 1 updates for velinotamig in November and CLN-049 in December.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed